 Home > Active Pharmaceutical Ingredients > Blood System Drugs > Liraglutide for Sale > High Quality GMP / FDA Certificated Liraglutide Powder CAS 204656-20-2 Liraglutide

High Quality GMP / FDA Certificated Liraglutide Powder CAS 204656-20-2 Liraglutide buy - large image1

High Quality GMP / FDA Certificated Liraglutide Powder CAS 204656-20-2 Liraglutide buy - image1

High Quality GMP / FDA Certificated Liraglutide Powder CAS 204656-20-2 Liraglutide buy - image2

High Quality GMP / FDA Certificated Liraglutide Powder CAS 204656-20-2 Liraglutide buy - image3

High Quality GMP / FDA Certificated Liraglutide Powder CAS 204656-20-2 Liraglutide buy - image4

High Quality GMP / FDA Certificated Liraglutide Powder CAS 204656-20-2 Liraglutide

Name: High Quality GMP / FDA Certificated Liraglutide Powder CAS 204656-20-2 Liraglutide
Brand: TNJONE
SKU: pr2406051091
Price: 200 USD
Availability: InStock

TDS 29 Inquiries

Unit Price: Get Latest Price 

CAS No.:

204656-20-2

Grade:

Pharmaceutical Grade

Content:

99%

Port:

CHINA ANY POET

Brand:

TNJONE

Packaging:

1g,10g,50g or according to customer's detail requirement.

Price valid (until):

2025-12-31

Contact Supplier

 Chat Now

Shaanxi TNJONE Pharmaceutical Co., Ltd

Company Type:

Manufactory

Location:

China

Qualification:

Main Products:

Semaglutide,Tirzepatide,API,Vitamins,Food Additive

 Visit Store

Product Description
Seller Information
Inquiry History

Description

High Quality GMP / FDA Certificated Liraglutide Powder CAS 204656-20-2 Liraglutide

What is Liraglutide ?

Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates secretion.

Liraglutide is a once-daily injectable derivative of the human incretin (metabolic hormone) glucagon-like peptide-1 (GLP-1), for the treatment of type 2 diabetes or obesity.
Type 2 diabetes
Liraglutide improves control of blood glucose. It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion.
In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes:
It acts in a glucose-dependent manner, meaning it will stimulate secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia.
It has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
It decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride.
It lowers blood triglyceride levels.
Obesity
Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.

Liraglutide is a once-daily injectable derivative of the human incretin (metabolic hormone) glucagon-like peptide-1 (GLP-1), for the treatment of type 2 diabetes or obesity.
Type 2 diabetes
Liraglutide improves control of blood glucose. It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion.
In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes:
It acts in a glucose-dependent manner, meaning it will stimulate secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia.
It has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
It decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride.
It lowers blood triglyceride levels.
Obesity
Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.

Items	Specifications
Product Name	Liraglutide
Cas No	204656-20-2
Einecs	810-818-7
MF	C172H265N43O51
MW	3751.202
Appearance	white powder
Melting Point	>182°C (dec.)
Shelf Life	2 Years When Properly Stored
Storage	Keep in a cool, dry, dark location in a tightly sealed container or cylinder.

Shop Wholesale Peptide Teriparatide Powder CAS 52232-67-4 Teriparatide Acetate-Detailed Image 1 Shop High Quality Oxyntomodulin Peptide Glucagon Acetate Powder CAS 16941-32-5 Glucagon-Detailed Image 2

Certification

Items	Specification
Appearance	White Powder
Assay	≥ 99%
Sieve analysis	≥ 95% through a USS#20
	≤ 75% through a USS#60
	≤ 15% through a USS#100
Loss on Drying	≤10%
Heavy Metal	≤20ppm
Total Plate Count	≤1000cfu/g
Yeast & Mold	≤100cfu/g
E.Coli	Negative
Salmonella	Negative
Staphylococcus	Negative

Function:

common to various degrees with other GLP-1 receptor agonists,liraglutide has advantages over more traditional therapies for type 2 diabetes:
1. Liraglutide acts in a glucose-dependent manner, meaning Liraglutide will stimulate insu.lin secretion only when blood glucose levels are higher than normal, preventing "overshoot".Consequently, Liraglutide shows negligible risk of hypoglycemia.
2. Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
3. Liraglutide decreases appetite and inhibits body weight gain,as shown in a head-to-head study versus glimepiride.
4. Liraglutide lowers blood triglyceride levels.

Company Information
Shop High Quality Oxyntomodulin Peptide Glucagon Acetate Powder CAS 16941-32-5 Glucagon-Detailed Image 3

Shop High Quality GMP / FDA Certificated Liraglutide Powder CAS 204656-20-2 Liraglutide-Detailed Image 4

FAQ

1.How to get in touch with us?

You can chat with us by Trademanager,WhatsApp or simply giving us an email, a phone call. All our contacts information can be found from our website.

2.Are you a manufacturer or trade company?

We are a professional manufacturer.

3.Can I get a sample?

Yes, free sample can be provided, but shipping cost is covered by your side.

4.What's your MOQ?

It is based on the different product. Some are 1g while some are 1 kg. Please be free to consult our salesman.

5.When can I get the quotation?
We usually quote within 1 hours after we get your inquiry. If it's a urgent order you can call us or mention it in your email subject, and we can take it as priority.

6.Is there any discount?
Yes, some products are applied for discount, but it depends on the quantity.

7.Can you do OEM for me?
Yes,we accept OEM orders, just contact us and give us your requirement. We will offer you a reasonable price and make samples ASAP.

ECHEMI Editorial Reference

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
Liraglutide is characterized as a white to almost white powder. It is freely soluble in aqueous base solutions (> 270 mg/mL), but its water solubility decreases below pH 7 and reaches its lowest level at pH 4-5 (approximately 0.05 mg/mL). Solubility increases marginally at pH 2.5 where it is very slightly soluble (≤ 0.8 mg/mL). Liraglutide is soluble in methanol (68 mg/mL) and very slightly soluble in ethanol (1.1 mg/mL). The isoelectric point of liraglutide is approximately 4.9. The pH of a 1 mg/mL aqueous solution of drug substance is approximately 9.3.
ChEBI: Liraglutide, a lipopeptide and polypeptide, is an analogue of human GLP-1 in which the lysine residue at position 27 is replaced by arginine and a hexadecanoyl group attached to the remaining lysine via a glutamic acid spacer. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Liraglutide functions as a glucagon-like peptide-1 receptor agonist and serves as a neuroprotective agent.
Liraglutide is GLP-1(1–37) modified at Ly: the -amino group is acylated with an (N-hexadecanoyl)glutam- -yl moiety that noncovalently but avidly binds tohuman serum albumin. (Also, Lys is conservatively replacedwith Arg.) These changes provide for a greatly extendedserum t12 of～10 to 15 hours after sc administration(0.6–1.8 mg), allowing for once-daily dosing.Liraglutide (Victoza, Novo Nordisk) is awaiting approvalby the FDA, EMEA, and the Koˉ roˉ -shoˉ (Japan).
Liraglutide peptide is a single, non-glycosylated polypeptide chain containing 31 amino acids, having a molecular mass of 3751 Dalton and a Molecular formula of C172H265N43O51.

Certificates

Basic Info

Product Name:

Liraglutide

Other Name:

Liraglutide;Glycine, L-histidyl-L-alanyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-alpha-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-(N-(1-oxohexadecyl)-L-gamma-glutamyl)-L-lysyl-L-alpha-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-;Liraglutida;Liraglutida [inn-spanish];Liraglutide [usan:inn];Liraglutidum;Liraglutidum [inn-latin];N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glp-1-(7-37)-peptide

CAS No.:

204656-20-2

Molecular Formula:

C172H265N43O51

InChIKeys:

YSDQQAXHVYUZIW-VTFFJMQZNA-N

Molecular Weight:

3751.202

Exact Mass:

3748.95000

EC Number:

810-818-7

Color/Form:

White to Off-White

Categories:

Blood System Drugs

Characteristics

PSA:

1513.76000

XLogP3:

6.12960

Melting Point:

>182°C (dec.)

Critical Temperature & Pressure:

Refrigerator

Research

Class:

GLP-1 receptor agonist (acylated GLP-1 analog, 31-amino-acid peptide)

Status:

FDA-approved (Victoza 2010, Saxenda 2014 for obesity)

Mechanism:

A 31-amino-acid GLP-1 analog with a C16 fatty-acid chain (palmitoyl) attached to Lys26 via a gamma-glutamic acid spacer. This fatty-acid modification enables reversible binding to serum albumin, extending the half-life to ~13 hours and allowing once-daily dosing. Activates GLP-1R to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite.

EC50 (GLP1R Ec50):

~10 nM

Source:

DrugBank: DB06655; Knudsen LB, et al. J Med Chem. 2000;43(9):1664-1669.DOI

Clinical Development:

NCT00781922; NCT01272219

FDA:

Victoza, Saxenda (approved 2010-01-25)

References

ChEMBL:

CHEMBL1213363

DrugBank:

DB06655

KEGG DRUG:

D09199

PubChem:

PubChem

Literature:

FDA: Victoza (NDA 022341); NEJM: Marso et al. (2016) — LEADER CV outcomes

Disclaimer:

Liraglutide is FDA-approved as a prescription medicine (Victoza for T2DM, Saxenda for obesity). This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.

See More Liraglutide Properties 

Hazard Identification

Classification of the substance or mixture

Carcinogenicity, Category 2

Reproductive toxicity, Category 2

GHS label elements, including precautionary statements

Precautionary statement(s)
Pictogram(s)
Signal word	Warning
Hazard statement(s)	H351 Suspected of causing cancer H361 Suspected of damaging fertility or the unborn child
Prevention	P203 Obtain, read and follow all safety instructions before use. P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
Response	P318 IF exposed or concerned, get medical advice.
Storage	P405 Store locked up.
Disposal	P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

Other hazards which do not result in classification

no data available

Handling and Storage

Precautions for safe handling

Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

Conditions for safe storage, including any incompatibilities

Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

See More Liraglutide Safety Data Sheet 

Seller Information

Business Type:
Manufactory

Main Products:
Semaglutide,Tirzepatide,API,Vitamins,Food Additive

Location:
No. 4C-11-A392, Financial Port, Northwest corner of Fengjing Avenue and Fengxin Road, Fengdong New City, Xi 'an, Shaanxi Province

Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

Average lead Time:
5

Total Annual Revenue:
$5 million-$10 million

Total Employees:
11-50

Year of Establishment:
2019

Shaanxi TNJONE Pharmaceutical Technology Co., LTD., located in the beautiful ancient capital Xi 'an, is committed to the peptide industry, pharmaceutical raw materials, food and feed additives, veterinary drugs and other fields, the enterprise adhering to provide customers with quality service, supply high-quality products, "world peace and health" as its responsibility, the company adhering to the "meet all customer requirements for products" as the service concept, Guarantee "provide qualified products" as the service principle, so that you get "God-like" noble shopping enjoyment. Our company has more than 1000 kinds of polypeptides, raw materials inventory, at any time to meet the various needs of customers for products. Is your best partner.

Inquiry History

29 Inquiries

Country	Product	Purchase Quantity	Date Posted
India	China factory wholesale price supply high purity 99% cas 204656-20-2 Liraglutide injection	50 KG	Sep 30, 2023
India	Liraglutide	1.00 KG	Oct 8, 2024
India	Liraglutide-USP	150.00 G	Oct 10, 2023
United Kingdom	Liraglutide	20 MG	Jul 8, 2026
United States	MIC	2 MT	May 20, 2026
United States	Mic (Lipo C with B12), VIP, Ss31, glutathione and, Reta	50 MG	Mar 4, 2026
Canada	Liraglutide	1 KG	Dec 8, 2025
United States	liraglutide	1 MT	Nov 22, 2025
Brazil	Liraglutida	1 G	Sep 29, 2025
United States	Liraglutide	1 KG	Aug 13, 2025
Sweden	liraglutide	1 KG	Aug 4, 2025
Pakistan	liraglutide injection	50 KG	Jan 21, 2025
India	Liraglutide	10 MG	Jul 17, 2024
United States	Peptide Liraglutide/Victoza/Liraglutida 98% Powder 67-51-6 Weight Loss Senwayer	1 KG	Sep 30, 2023
Jordan	Liraglutide	1.00 MT	Sep 19, 2023
India	liraglutide	1 KG	Feb 25, 2026
United States	liraglutide	1	Jan 21, 2026
Reunion Island	Liraglutide	1 G	Apr 14, 2025
United States	Liraglut	1 MT	Feb 9, 2025
Israel	Liraglutide	1 G	Aug 26, 2024

Go to Page

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Price	Supplier Name	Details
Pharmaceutical Peptide cas204656-20-2 Raw Powder Liraglutide GLP-1 Analogue 3mg 5mg 10mg vials	Pharmaceutical Grade/99			Inquiry
Liraglutide	Pharmaceutical Grade/99		Echemi Pharmaceutical	Inquiry
Liraglutide Purity 99% white powder	Research and Industrial Grade/98.00		Hangzhou Go Top Peptide Biotech Co.,Ltd.	Inquiry
Liraglutide 99% (recombinant)	Pharmacy Grade(for injection)/99		First Rays Co.,Ltd	Inquiry
99% Purity Peptides Mic (lipo C with B12) for Supports Energy Metabolism with Fast Delivery	Pharmaceutical Grade/99	$11.3-11.6/UNIT FOB	DALIAN HANDOM CHEMICALS CO.,LTD.	Inquiry